(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Instructions to Decide whether a Fender bender Legal counselor is Required for Your Particular Case - 22 ways you can conserve the water used to make your food
- 3Cuba says 33 have died of mosquito-borne illnesses as epidemic rages
- 4Step by step instructions to Buy a Jeep Wrangler on a Senior's Spending plan
- 5International issues on the agenda as Frances's Macron visits China
- 2025 Yachting Editors' Choice Awards: Yachts
- Mont Blanc road tunnel reopens to traffic after 15 weeks of repairs
- Moscow accuses Berlin of stifling the opposition
- Vote In favor of Your #1 Method for diminishing Pressure
- High Court freezes government move to shutter Army Radio pending ruling
- Thousands of Walgreens nasal spray bottles recalled. See which ones.
- Day to day Temporary Positions That Compensate Fairly in the US
- Which Startup's Innovation Could Reform Medical care?
- Exploring the Mind boggling Universe of Connections: Individual Bits of knowledge
